Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團（天津）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6821)

CLARIFICATION ANNOUNCEMENT REVISED FORM OF PROXY FOR THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 (APPLICABLE TO H SHAREHOLDERS)

Reference is made to the proxy form (the "**Original Proxy Form**") for use at the second extraordinary general meeting of 2025 (the "**EGM**") of Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司) (the "**Company**") to be held physically at 2:00 p.m. on Wednesday, 6 August 2025 at No. 71, 7th Street, Economic – Technological Development Area, Tianjin, the PRC (or any adjournment thereof) despatched with the circular (the "**Circular**") and the notice of the EGM (the "**Notice of EGM**") of the Company both dated 22 July 2025. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Circular and the Notice of EGM.

The Company wishes to clarify that, for the avoidance of doubt, since the voting in respect of (i) Resolution No. 6 and Resolution No. 7 as a whole (collectively, the "**Resolutions No. 6 and No. 7**") and (ii) Resolution No. 8 shall be conducted by way of cumulative voting, respectively, the number of cumulative votes cast for each of the candidates for (i) the executive Directors and non-executive Director, and (ii) the independent non-executive Directors (as the case may be) shall be specified in the boxes marked "Cumulative Votes" for such resolution directly next to the corresponding candidates. The Company further added notes explaining how the cumulative votes shall be cast for Resolutions No. 6 and No. 7 and Resolution No. 8.

In light of the above, the Company has revised the Original Proxy Form to modify its format. The revised proxy form for use at the EGM (the "**Revised Proxy Form**") will be published on the websites of the Hong Kong Stock Exchange on 22 July 2025 and despatched to the Shareholders on 23 July 2025. The format modification as reflected in the Revised Proxy Form does not affect any of the other information contained in the Original Proxy Form and the information contained in the Circular and the Notice of AGM remain unchanged.

Shareholders should note that the Revised Proxy Form supersedes and replaces the Original Proxy Form and that the Original Proxy Form is void and invalid. Shareholders who have duly completed and returned the Original Proxy Form should complete and return the Revised Proxy Form in accordance with the instructions provided therein.

To be valid, the Revised Proxy Form and, if such Revised Proxy Form is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority must be delivered to the Company's H Shares Registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (in the case of the Revised Proxy Form by holders of H shares) not less than 24 hours before the time for holding of the EGM (i.e. before 2:00 p.m. on Tuesday, 5 August 2025) or not less than 24 hours before the holding of any adjournment thereof. Under such circumstances, the Shareholders should use the Revised Proxy Form and should not return the Original Proxy Form.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
Chairperson of the Board, Executive Director and Chief Executive Officer

Tianjin, the PRC, 22 July 2025

As at the date of this notice, the Board comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da, and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Lee, Kar Chung Felix as independent non-executive Directors.